Drug intelligence / Profile preview

Jiangtang decoction

Development stage: Unknown
Lead developer: Peking University First Hospital
Administration: Oral

Overview

Jiangtang decoction is a Traditional Chinese Medicine (TCM) herbal formulation being investigated for its potential to mitigate metabolic side effects associated with antipsychotic medication. Specifically, it is being studied by Peking University First Hospital for its ability to improve olanzapine-induced weight gain in patients with schizophrenia. The proposed mechanism involves the modulation of gut microbiota, specifically by promoting the growth of beneficial probiotics and inhibiting pathogenic bacteria, thereby addressing intestinal dysbiosis and metabolic syndrome.

Other names: Jiangtang Tang

Beyond the preview

Go deeper on Jiangtang decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangtang decoction.

Explore the full profile